Innovent Biologics (01801.HK): 1H Product Revenue Exceeds RMB 8.2 Billion, Up Over 55% YoY; Q2 Exceeds RMB 4.3 Billion

NewTimeSpace News: Innovent Biologics, Inc. (stock code: 1801) announced that for the first half of 2026, product revenue exceeded RMB 8.2 billion, representing year-on-year growth of over 55%. Second-quarter product revenue exceeded RMB 4.3 billion, up approximately 60% year-on-year. The company attributed the strong performance to its "dual-engine" strategy, with core products including Mazdutide, Tafolecimab, and Tislelizumab N01 driving growth. Market penetration continued to increase for five TKIs newly added to the National Reimbursement Drug List.

The company expanded into breast cancer treatment through a commercialization partnership with Eli Lilly for Verzenio in mainland China. Three core innovative assets are advancing into global Phase III trials, with over 20 collaboration projects with multinational pharmaceutical companies including Pfizer, Eli Lilly, Takeda, and Roche.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.